Scientist.com

Name: Scientist.com
Brand: Scientist.com

The world's largest marketplace for life science.

Est 2007|Valuation $130M|Raised $43.5M|25 Ref Customers

LinkedIn 11K|Web traffic 26K|FTEs 131|HQ San Diego, California, US

MarketsSource-to-Contract eSourcing

Published Oct 15, 2026

01Common complaints

1. **Primary need is lab inventory and simple supply ordering** - A lab operations tool with transparent SaaS pricing (e.g., Quartzy) may be a simpler option. 2. **Requirement for transparent pricing and quick self-serve onboarding** - The vendor operates an enterprise/demo-led sales motion; organizations needing predictable per-seat pricing and rapid self-serve onboarding may prefer alternatives. 3. **Sourcing is dominated by a few strategic CROs under long-term MSAs** - Organizations with most spend already consolidated under existing MSAs may not realize significant additional value from a broad marketplace. 4. **Need for comprehensive, publicly documented security/compliance specifics** - While SOC 2 is stated, many security details (ISO certifications, pen test summaries, sub-processor lists) are not available in the public material reviewed; highly regulated buyers should request detailed documentation. 5. **Dependence on broad third-party review validation** - With limited presence on major review platforms, independent validation of satisfaction and support quality will rely more on references and pilots.

Deal disqualifiers (poor fit)

Teams seeking a lightweight purchasing tool with public pricing and minimal implementation
Organizations with low outsourcing complexity (few suppliers, limited regulated categories)
Highly bespoke procurement processes that cannot conform to standardized workflows

Publicly visible limitations

Limited public pricing transparency (demo-driven sales model)
Limited public third-party review coverage (major review sites showed no substantial review base in the reviewed searches)
Security/compliance details are presented at a high level (SOC 2 claim and GDPR/EU hosting claims are present, but more detailed documentation was not found in the public material reviewed)

Roadmap / "coming soon" features

The vendor’s AI tools page references features described as forthcoming (for example, project timeline prediction), indicating some predictive functionality may not yet be generally available.

02Why they buy

Strengths that appear differentiated (vendor-stated)

- The vendor states a multi-thousand-supplier network spanning research services and products. - Vendor-described compliance programs and supplier pre-assessment processes (e.g., COMPLi and VERIF.i) are positioned as core capabilities. - The platform combines supplier discovery, bidding, contracting, compliance, and spend analytics in a single orchestration layer (per vendor materials). - The vendor describes generative-AI-assisted procurement features for supplier selection and workflow assistance.

Where competitors may have advantages

- **Transparency and ease of buying**: some competitors provide published pricing and self-serve purchasing models that reduce procurement friction. - **Broad eProcurement integration**: large enterprise eProcurement suites may be stronger for non-R&D categories and global procurement standardization, though they may require additional configuration to support regulated R&D services. - **Independent proof**: competitors with more third-party reviews offer more external validation of product experience.

03Field reports

Review-platform availability (important limitation)

A major constraint in evaluating Scientist.com via typical SaaS review channels is the limited public review coverage: - G2 and other mainstream review sites show limited substantive review content for the product in the searches reviewed. - Capterra reviews were not identified in the reviewed results. This absence is not uncommon for niche enterprise platforms sold into regulated life science procurement, but it increases buyer risk because there is less third-party user sentiment to consult.

Vendor-published testimonials (marketing; treated as vendor-sourced)

The vendor’s homepage includes vendor-selected testimonials attributed to buyer-role titles (for example, an Outsourcing Lead / Sourcing Expert) describing the platform as beneficial to their process. Such testimonials are vendor-selected and should be treated as illustrative rather than independently validated.

Community / social proof (Reddit / Hacker News)

Targeted searches did not surface meaningful Reddit or Hacker News threads discussing product experience for this vendor. Searches returned limited or unrelated results.

Implication: procurement teams will likely need to rely on direct references, customer calls, pilots, and security/procurement diligence rather than broad community sentiment.

What customers appear to value (inferred from case-style press)

From public press releases and vendor positioning, recurring value themes include:

access to a pre-vetted supplier network
reduced contracting delays via standardization and vendor due diligence
compliance tooling for regulated categories
analytics and procurement governance

Why some customers might not buy / deal-breakers (inferred)

Based on the product positioning and typical procurement considerations, common disqualifiers may include:

preference for fully in-house vendor management and existing CRO master agreements
organizations that primarily buy standard lab supplies (vs outsourced services) and already have strong catalogs and punchouts
teams that require transparent self-serve pricing and rapid adoption without enterprise implementation

Major pharmaceutical extension (public press release; credibility: medium)

A press release describes a major pharmaceutical expanding its use of the platform, elevating the vendor to a preferred global channel for sourcing external R&D services, with rollout expectations for additional scope over the following months. - **Strength**: a named enterprise customer can provide a useful reference point. - **Limitations**: benefits and outcomes are described qualitatively; ROI and cost-savings claims were not independently audited in the sources reviewed.

Supplier-side subscription case study (vendor marketing site; credibility: low–medium)

A vendor marketing page describes suppliers on paid subscription tiers reporting increases in profile views, orders, and requests over a one-year window. - **Strength**: directional information on supplier-side monetization and engagement. - **Concerns**: - methodology is unclear (selection bias is possible if higher-performing suppliers are more likely to subscribe) - before-vs-after comparisons without a control group can overstate impact - the content is vendor marketing and does not constitute independent verification of buyer outcomes

Supplier recognition award (supplier blog; credibility: low)

A supplier blog post described receiving a marketplace supplier recognition award.

Value: indicates supplier engagement and marketplace activity.
Limitations: promotional content from a supplier; it does not validate buyer outcomes.

04Best fit

Company size

Best fit appears to be:

Biopharma enterprises and larger biotechs with meaningful external R&D spend and compliance requirements.
Large organizations (500+ employees), or smaller companies with a high degree of outsourcing and a formal procurement function.

Industries / verticals

Pharmaceuticals
Biotech
CRO ecosystem participants (as suppliers)
Potentially research-focused public sector entities

Roles and personas

Decision makers: Head of R&D Procurement, Strategic Sourcing, Outsourcing Leads, VP Procurement, Finance/Compliance stakeholders
End users: Scientists requesting studies/services, vendor managers, sourcing analysts

Pain points addressed

Fragmented supplier discovery
Long contracting cycles
Compliance risk in regulated service categories
Poor visibility into outsourced R&D spend

Qualification criteria (good fit)

High volume of outsourced studies across multiple categories
Need for standardized SOW/RFQ processes
Governance requirements (ethics, regulated studies, vendor due diligence)
Desire to consolidate suppliers under a single orchestration layer

05The pitch

What the product does (objective value proposition)

Scientist.com is an R&D procurement orchestration platform and marketplace for life sciences R&D. It connects buyers (pharma/biotech and some academic institutions) with a network of pre-qualified suppliers (CROs, specialized service providers, and product vendors). Core workflows include: - supplier discovery and RFx-style project scoping - quote collection/comparison and negotiation support (including rate cards) - contracting and compliance gating - purchasing/approvals, billing, and supplier management - spend analytics and procurement controls The vendor positions the platform as more than a simple marketplace, describing it as a procurement orchestration model with vendor-described generative-AI-assisted procurement support referred to by the vendor as Procurement CoPilot. Vendor claims should be validated during customer diligence.

Target market and positioning

Primary target: enterprise life science organizations with complex outsourced R&D spend (especially large pharma and larger biotechs), plus procurement, outsourcing, and vendor-management teams.
Positioning: presented as a unified platform intended to support supplier discovery → compliance → contracting → purchasing → analytics, with a vetted supplier network and AI-based decision support (as described by the vendor).

Get a comprehensive analysis of Scientist.com including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 15, 2026

01Common complaints

Primary need is lab inventory and simple supply ordering
- A lab operations tool with transparent SaaS pricing (e.g., Quartzy) may be a simpler option.
Requirement for transparent pricing and quick self-serve onboarding
- The vendor operates an enterprise/demo-led sales motion; organizations needing predictable per-seat pricing and rapid self-serve onboarding may prefer alternatives.
Sourcing is dominated by a few strategic CROs under long-term MSAs
- Organizations with most spend already consolidated under existing MSAs may not realize significant additional value from a broad marketplace.
Need for comprehensive, publicly documented security/compliance specifics
- While SOC 2 is stated, many security details (ISO certifications, pen test summaries, sub-processor lists) are not available in the public material reviewed; highly regulated buyers should request detailed documentation.
Dependence on broad third-party review validation
- With limited presence on major review platforms, independent validation of satisfaction and support quality will rely more on references and pilots.

Deal disqualifiers (poor fit)

Teams seeking a lightweight purchasing tool with public pricing and minimal implementation
Organizations with low outsourcing complexity (few suppliers, limited regulated categories)
Highly bespoke procurement processes that cannot conform to standardized workflows

Publicly visible limitations

Limited public pricing transparency (demo-driven sales model)
Limited public third-party review coverage (major review sites showed no substantial review base in the reviewed searches)
Security/compliance details are presented at a high level (SOC 2 claim and GDPR/EU hosting claims are present, but more detailed documentation was not found in the public material reviewed)

Roadmap / "coming soon" features

The vendor’s AI tools page references features described as forthcoming (for example, project timeline prediction), indicating some predictive functionality may not yet be generally available.

02Why they buy

Strengths that appear differentiated (vendor-stated)

The vendor states a multi-thousand-supplier network spanning research services and products.
Vendor-described compliance programs and supplier pre-assessment processes (e.g., COMPLi and VERIF.i) are positioned as core capabilities.
The platform combines supplier discovery, bidding, contracting, compliance, and spend analytics in a single orchestration layer (per vendor materials).
The vendor describes generative-AI-assisted procurement features for supplier selection and workflow assistance.

Where competitors may have advantages

Transparency and ease of buying: some competitors provide published pricing and self-serve purchasing models that reduce procurement friction.
Broad eProcurement integration: large enterprise eProcurement suites may be stronger for non-R&D categories and global procurement standardization, though they may require additional configuration to support regulated R&D services.
Independent proof: competitors with more third-party reviews offer more external validation of product experience.

03Field reports

Review-platform availability (important limitation)

A major constraint in evaluating Scientist.com via typical SaaS review channels is the limited public review coverage:

G2 and other mainstream review sites show limited substantive review content for the product in the searches reviewed.
Capterra reviews were not identified in the reviewed results.

This absence is not uncommon for niche enterprise platforms sold into regulated life science procurement, but it increases buyer risk because there is less third-party user sentiment to consult.

Vendor-published testimonials (marketing; treated as vendor-sourced)

Community / social proof (Reddit / Hacker News)

Targeted searches did not surface meaningful Reddit or Hacker News threads discussing product experience for this vendor. Searches returned limited or unrelated results.

Implication: procurement teams will likely need to rely on direct references, customer calls, pilots, and security/procurement diligence rather than broad community sentiment.

What customers appear to value (inferred from case-style press)

From public press releases and vendor positioning, recurring value themes include:

access to a pre-vetted supplier network
reduced contracting delays via standardization and vendor due diligence
compliance tooling for regulated categories
analytics and procurement governance

Why some customers might not buy / deal-breakers (inferred)

Based on the product positioning and typical procurement considerations, common disqualifiers may include:

preference for fully in-house vendor management and existing CRO master agreements
organizations that primarily buy standard lab supplies (vs outsourced services) and already have strong catalogs and punchouts
teams that require transparent self-serve pricing and rapid adoption without enterprise implementation

Major pharmaceutical extension (public press release; credibility: medium)

Strength: a named enterprise customer can provide a useful reference point.
Limitations: benefits and outcomes are described qualitatively; ROI and cost-savings claims were not independently audited in the sources reviewed.

Supplier-side subscription case study (vendor marketing site; credibility: low–medium)

A vendor marketing page describes suppliers on paid subscription tiers reporting increases in profile views, orders, and requests over a one-year window.

Strength: directional information on supplier-side monetization and engagement.
Concerns:
- methodology is unclear (selection bias is possible if higher-performing suppliers are more likely to subscribe)
- before-vs-after comparisons without a control group can overstate impact
- the content is vendor marketing and does not constitute independent verification of buyer outcomes

Supplier recognition award (supplier blog; credibility: low)

A supplier blog post described receiving a marketplace supplier recognition award.

Value: indicates supplier engagement and marketplace activity.
Limitations: promotional content from a supplier; it does not validate buyer outcomes.

04Best fit

Company size

Best fit appears to be:

Biopharma enterprises and larger biotechs with meaningful external R&D spend and compliance requirements.
Large organizations (500+ employees), or smaller companies with a high degree of outsourcing and a formal procurement function.

Industries / verticals

Pharmaceuticals
Biotech
CRO ecosystem participants (as suppliers)
Potentially research-focused public sector entities

Roles and personas

Decision makers: Head of R&D Procurement, Strategic Sourcing, Outsourcing Leads, VP Procurement, Finance/Compliance stakeholders
End users: Scientists requesting studies/services, vendor managers, sourcing analysts

Pain points addressed

Fragmented supplier discovery
Long contracting cycles
Compliance risk in regulated service categories
Poor visibility into outsourced R&D spend

Qualification criteria (good fit)

High volume of outsourced studies across multiple categories
Need for standardized SOW/RFQ processes
Governance requirements (ethics, regulated studies, vendor due diligence)
Desire to consolidate suppliers under a single orchestration layer

05The pitch

What the product does (objective value proposition)

supplier discovery and RFx-style project scoping
quote collection/comparison and negotiation support (including rate cards)
contracting and compliance gating
purchasing/approvals, billing, and supplier management
spend analytics and procurement controls

The vendor positions the platform as more than a simple marketplace, describing it as a procurement orchestration model with vendor-described generative-AI-assisted procurement support referred to by the vendor as Procurement CoPilot. Vendor claims should be validated during customer diligence.

Target market and positioning

Primary target: enterprise life science organizations with complex outsourced R&D spend (especially large pharma and larger biotechs), plus procurement, outsourcing, and vendor-management teams.
Positioning: presented as a unified platform intended to support supplier discovery → compliance → contracting → purchasing → analytics, with a vetted supplier network and AI-based decision support (as described by the vendor).

Get a comprehensive analysis of Scientist.com including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →